Overview Vestipitant 28-day Tolerance Study Status: Completed Trial end date: 2009-09-01 Target enrollment: Participant gender: Summary This study is a 28-day polysomnographic and subjective assessment of oral Vestipitant 15mg/day for treatment of Primary Insomnia in adults outpatients. Phase: Phase 2 Details Lead Sponsor: GlaxoSmithKlineTreatments: Vestipitant